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ABSTRACT
People with diabetes are at greater risk for neg-
ative outcomes from COVID-19. Though this
risk is multifactorial, poor glycaemic control
before and during admission to hospital for
COVID-19 is likely to contribute to the
increased risk. The COVID-19 pandemic and
restrictions on mobility and interaction can also
be expected to impact on daily glucose man-
agement of people with diabetes. Telemonitor-
ing of glucose metrics has been widely used
during the pandemic in people with diabetes,
including adults and children with T1D, allow-
ing an exploration of the impact of COVID-19
inside and outside the hospital setting on gly-
caemic control. To date, 27 studies including
69,294 individuals with T1D have reported the
effect of glycaemic control during the COVID-
19 pandemic. Despite restricted access to dia-
betes clinics, glycaemic control has not deteri-
orated for 25/27 cohorts and improved in 23/27
study groups. Significantly, time in range (TIR)
70–180 mg/dL (3.9–10 mmol/L) increased
across 19/27 cohorts with a median 3.3%
(- 6.0% to 11.2%) change. Thirty per cent of
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the cohorts with TIR data reported an average
clinically significant TIR improvement of 5% or
more, possibly as a consequence of more accu-
rate glucose monitoring and improved connec-
tivity through telemedicine. Periodic
consultations using telemedicine enables care
of people with diabetes while limiting the need
for in-person attendance at diabetes clinics.
Reports that sustained hyperglycaemia and
early-stage diabetic ketoacidosis may go
untreated because of the lockdown and con-
cerns about potential exposure to the risk of
infection argue for wider access to glucose tele-
monitoring. Therefore, in this paper we have
critically reviewed reports concerning use of
telemonitoring in the acute hospitalized setting
as well as during daily diabetes management.
Furthermore, we discuss the indications and
implications of adopting telemonitoring and
telemedicine in the present challenging time, as
well as their potential for the future.
Keywords: Diabetes; Insulin pumps;
Continuous glucose monitoring; Ambulatory
glucose profile; Virtual care; COVID-19;
Mortality; Risk management; Telemonitoring;
Telemedicine
Key Summary Points
Despite restricted access to standard
clinical care during the COVID-19
pandemic, glycaemic control has not
deteriorated for people with type 1
diabetes using telemonitoring of glucose
data.
The increased risk profile for severe
COVID-19 disease on hospital admission
for people with diabetes can be mitigated
by application of telemonitoring and
glucose-lowering treatment immediately
following admission.
Routine telemonitoring can identify
groups of at-risk individuals with diabetes
who need in-person consultation and
care, as well as those who may be
successfully managed with telemedicine.
The COVID-19 pandemic has highlighted
the unmet need for wider application of
telemedicine and telemonitoring via CGM
for people with diabetes, including those
with hyperglycaemia and early-stage
diabetic ketoacidosis that may go
untreated during times of restricted
clinical access.
The efficacy of diabetes digital health
ecosystems has been validated during the
COVID-19 public health emergency and
argues for accelerated implementation of
these models of care in diabetes.
INTRODUCTION
Following the outbreak and spreading of
COVID-19, it became clear from analyses car-
ried out in China, USA, Italy and UK that people
with diabetes hospitalized for COVID-19 have
higher risks of more severe outcomes, including
increased risk of death [1–5]. A meta-analysis
including 83 studies [6] confirmed that people
with pre-existing diabetes admitted to hospital
because of COVID-19 had a twofold higher risk
of requiring intensive unit care (n = 22 studies;
odds ratio 2.10) and a nearly threefold higher
risk of in-hospital death (n = 15 studies; odds
ratio 2.68). However, there are significant
regional differences, with diabetes-related risks
being more prominent in non-Asian versus
Asian countries [6]. Outcomes have been
claimed to differ between T1D and T2D with the
risk of dying in hospital with COVID-19 being
3.5-fivefold higher in T1D and twofold in T2D
compared to people without diabetes [5, 6].
When adjusted for previous hospital admissions
with coronary heart disease, cerebrovascular
disease or heart failure, these increased risks for
dying in hospital after contracting COVID-19
are 2.86 and 1.81 in T1D and T2D, respectively.
Mortality risk increases with age both in T1D
and T2D and is emphasised in people over
70 years old, with the highest risks being for
people over 80 years of age (relative risk 4.79 in
T1D, 4.52 in T2D) [7]. However, it appears, that
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in T1D, only people over 50 years old, with
longer duration of the disease (80% with more
than 15 years of disease) and raised HbA1c[
10% (86 mmol/mol) are at higher risk of severe
clinical outcomes of COVID-19 [4]. Amongst
people with diabetes, those with prior hospital
admission for diabetic ketoacidosis (DKA) or
severe hypoglycaemia in the past 5 years were
three times more likely to develop fatal or crit-
ical care unit-treated COVID-19 [8]. Notably,
children and adolescents with diabetes do not
appear to be at risk of more severe outcomes
with COVID [9, 10]. Prevalence, outcomes and
prognosis in this group appear to be no different
from their non-diabetic counterparts and con-
sistently milder than adults with diabetes. A
visual summary of the known risk factors is
shown in Fig. 1.
The need to reduce the risk of community
transmission of COVID-19 for vulnerable
groups led to national guidance for people with
diabetes to undertake extreme social distancing
and shielding in place that minimises infection
risk, including attendance at diabetes clinics.
Extreme social distancing during the global
COVID-19 pandemic meant that people with
diabetes have reduced or had no access to their
regular face-to-face diabetes services, being
replaced in most cases with a reduced frequency
of telephone or video consultations. For people
with diabetes who can uplink glucose data to
the cloud and connect remotely with their
healthcare provider, such as users of continuous
Box 1. Definitions for Telemedicine and Telemonitoring in Context of Diabetes Care
Telemedicine Managing diabetes care using telecommunications technology, including telephone and video
conferencing, to deliver care at a distance. In this way, a healthcare professional (HCP) in one
location can provide a medical consultation, including treatment adjustment, to a patient at a distant
site. Telemedicine can also involve multiple HCPs in a synchronous patient consultation or care
review.
Telemonitoring The use of diabetes-specific medical devices that can monitor, transmit and share indicators of diabetes
health between a person with diabetes and their diabetes care team. Telemonitoring allows care of
patients at home or at other locations remote from their HCPs, using mobile phones, tablet
computers, and desktop computers. Telemonitoring allows information, such as interstitial glucose
readings from CGM systems, to be stored and reviewed by separate members of the diabetes care
team, including the patient.
Fig. 1 Risk matrix for people during the COVID-19
pandemic. Summary of the known risk factors for
infection and disease severity with COVID 19. eGFR
estimated glomerular filtration rate (ml/min/1.73 m2),
T1D type 1 diabetes, T2D type 2 diabetes
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Table 1 Studies reporting glycaemic metrics before and during COVID-19 social lockdown
Study Region Adults/
children (n)
Type System Change in glycaemic
metrics
Bonora BM [17] Italy Adults (33) T1D FreeStyle Libre AG, mg/dL 177–160
(p = 0.005)





Capaldo B [19] Italy Adults (207) T1D FreeStyle Libre (n = 130)
Medtronic Guardian (n = 47)
Dexcom G6 (n = 18)















Greece Children (34) T1D Medtronic Enlite %CV 39.5–37.4
(p = 0.011)








eA1c 7.4–7.1 (p\ 0.001)
Mesa A [15] Spain Adults (92) T1D Free Style Libre (n = 75)
Dexcom G5 (n = 17)
%TIR 59.3–62.6 (p\ 0.05)
%TAR1 34.4–30.7
(p\ 0.05)
GMI, % 7.2–7.0 (p\ 0.05)








Spain Adults (44) T1D FreeStyle Libre No change during
lockdown




Aragona M [81] Italy Adults (63) T1D FreeStyle Libre (n = 52)
Dexcom G6 (n = 11)
AG, mg/dL 165–158
(p = 0.04)
%TIR 58–61 (p\ 0.05)
%TAR1 38–34 (p\ 0.04)
GMI, % 7.2–7.0
(p = 0.016)
Dover AR [22] UK Adults (572) T1D FreeStyle Libre AG, mmol/L 9.6–9.3
(p\ 0.001)
%TIR 53–56 (p\ 0.001)
%TBR 3-3 (p = 0.005)
%TAR1 42–39 (p\ 0.001)
eA1c 61–58 (p\ 0.001)
Di Dalmazi G [82] Italy Children
B 12 years
(30)
T1D Freestyle Libre (n = 2)
Dexcom G5 or G6 (n = 28)
SD 67.4–64.3 (p = 0.029)
Di Dalmazi G [82] Italy Teenagers
13–17 years
(24)
T1D Freestyle Libre (n = 2)
Dexcom G5 or G6 (n = 22)
No change during
lockdown




Type System Change in glycaemic
metrics
Di Dalmazi G [82] Italy Adults (76) T1D Freestyle Libre (n = 41)











SD 63.0–59.6 (p = 0.016)
eA1c, % 7.2–6.8
(p\ 0.001)
GMI,% 7.7–7.6 (p = 0.001)
Brener A [83] Israel Children (102) T1D Dexcom G5 No change during
lockdown








GMI,% 7.2–6.9 (p\ 0.001)
Prabhu Navis J
[18]
UK Adults (269) T1D Freestyle Libre (n = 190)
Dexcom G6 (n = 79)
%TIR 57.5–59.6
(p = 0.002)
%CV 37–36 (p = 0.003)




%TIR 75–69 (p\ 0.001)
%TBR1 6–10 (p = 0.002)
eA1c 7.3–7.5 (p = 0.031)




Type System Change in glycaemic
metrics








Braune K [23] Germany Children (28) T1D Freestyle Libre (n = 9)
Dexcom G5/G6 (n = 6)





Potier L [20] France Adults (1378) T1D FreeStyle Libre AG, mmol/L 9.1–8.7
(p\ 0.001)
Boscari F [24] Italy Adults (79) T1D FreeStyle Libre (n = 52)
Dexcom (n = 16)









Spain Children (80) T1D FreeStyle Libre (n = 15)
Medtronic Guardian (n = 52)
Dexcom G6 (n = 13)













Type System Change in glycaemic
metrics
Rachmiel M [25] Israel Children (195) T1D Unspecified CGM AG, mg/dL 164–160
(p\ 0.001)







Marigliano M [87] Italy Children (233) T1D FreeStyle Libre (n = 98)
Dexcom G6 (n = 100)







SD 68.0–63.6 (p\ 0.001)
GMI, % 7.60–7.37
(p\ 0.001)
Alharthi SK [26] Saudi
Arabia
Adults (101) T1D Unspecified CGM AG, mg/dL 180–159
(p\ 0.001)
%TIR 46–55 (p\ 0.001)
%TAR1 48–35 (p\ 0.001)
GMI,% 7.7–7.2 (p = 0.03)
van der Linden J
[88]
USA NA (65,067) All Dexcom G6 %TIR 59–61 (p\ 0.001)
2296 Diabetes Ther (2021) 12:2289–2310
glucose monitoring (CGM), including flash
glucose monitoring, clinical review of glucose
control and shared decision-making in regard to
treatment adjustment has been accomplished
via telemedicine and glucose telemonitoring
tools. Substantial evidence now indicates that
this has been effective (Table 1). Routine care
was then effectively switched to telemedicine
and digital services, including for diabetes
reviews and self-management support, and
published data has demonstrated that glucose
control was not impaired while access to regular
diabetes clinical services was interrupted [11].
This review summarises available data on the
importance both of telemonitoring and tele-
medicine, as defined in Box 1, in effective dia-
betes management for reducing the risks for
COVID-19 infection. This article is based on
previously conducted studies and does not
contain any new studies with human partici-
pants or animals performed by any of the
authors.
STUDIES REPORTING GLUCOSE
METRICS BEFORE AND DURING
COVID-19 SOCIAL LOCKDOWN
Studies were reviewed that reported data on
remote monitoring with CGM technologies
that has enabled clinicians and people with
diabetes to view and discuss glucose downloads
together during this period. In the absence of
routine laboratory HbA1c testing, several stud-
ies, since the start of the COVID-19 pandemic,
have used percentage time in range (%TIR) and
other CGM-derived metrics [12] to determine
the degree of glycaemic control. %TIR is indeed
becoming established as a significant indicator
of immediate and medium-term glucose control
[13]. Table 1 summarises the various studies
published between March 2020 and March
2021. Each of the studies selected individual
before and during lockdown criteria for com-
parison of glucose metrics, typically bench-
marking lockdown as starting in the middle to
end of March 2020.
TIME IN RANGE DURING COVID-19
Across the 27 cohorts studied, %TIR increased
significantly in 19 of them, and did not change
in 7 of them. Significantly, time in range (TIR)
70–180 mg/dL/3.9–10 mmol/L improved across
18/27 cohorts with a median change (range) of
3.3% (- 6.0 to 11.2%), covering 67,587 indi-
viduals using CGM sensors. Notably, 30% of the
cohorts with TIR data reported clinically signifi-




Type System Change in glycaemic
metrics






Studies are listed in date order as disclosed on PubMed. Significant changes in glycaemic metrics from before to during
COVID-19 lockdown are presented. Each number sequence indicates change from before to during lockdown with p value
AG average glucose, eA1c estimated HbA1c, %CV % coefficient of mean glucose, GMI glucose management indicator, %TIR
percentage time in range 70–180 mg/dL (3.9–10 mmol/L), %TBR1 percentage time below range\ 70 mg/dL (3.9 mmol/
L), %TBR2 percentage time below range\ 54 mg/dL (3.0 mmol/L), %TAR1 percentage time above range[ 180 mg/dL
(10 mmol/L), %TAR1 percentage time above range[ 250 mg/dL (13.8 mmol/L), TDD total daily dose of bolus insulin,
NA no information about demogaphics
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in the study by Barchetta et al. [14] did %TIR
deteriorate during the lockdown period. In this
study, lockdown-associated stress due to loss of
work or furlough from work independently pre-
dicted impaired TIR after adjustment for poten-
tial confounders. Subjects in this study also
experienced an increase in percentage time
above range (%TAR) and percentage time below
range (%TBR) during the lockdown. This aligns
with observations from Bonora et al. [17], who
have reported that improvements in %TIR and
%TAR were restricted to those who stayed at
home during lockdown, whereas those still
experiencing the stress of on-site working saw no
change. Reductions in TAR and in average glu-
cose are present in 13/27 cohorts and 13/27
cohorts, respectively, indicative of the increases
in %TIR. %TBR\70 mg/dL (\3.9 mmol/L)
decreased only in 4/27 cohorts and increased in
3/27 cohorts, with no change in the rest,
including in subjects prone to hypoglycaemia
[16, 17]. When reported, improvements in %TIR
in T1D after lockdown are negatively associated
with baseline %TIR [18], with greater improve-
ments seen for people with lower %TIR pre-
lockdown. Baseline HbA1c is also predictive of
greater improvement in %TIR, such that people
in whom %TIR improved by 5% or more were
more likely to have a higher pre-lockdown
HbA1c [18].
It has been suggested that restrictions on
community, social and leisure time provided
more time for diabetes self-management during
the lockdown periods and may have contributed
to improved glycaemic control in this period.
Again, in favour of this idea are the outcomes
from the cohort in Italy, showing that CGM
users who stayed at home during lockdown had
significant improvements in average glucose and
%TIR, whereas those who continued working
did not. Capaldo and colleagues [19] indicated
that improvements in %TIR and reduced gly-
caemic variability amongst their cohort are
associated with reduced physical activity, more
regular meal patterns and a change in sleeping
patterns. Equally, the reduction in average glu-
cose reported by Potier [20] was associated with
positive behavioural changes. The importance
and efficacy of greater parental care of children
with T1D while access to standard paediatric care
is interrupted has been shown by another Italian
study on 22 children [21] that showed a signifi-
cant increase in %TIR and reduction in %TAR
during COVID-enforced home care for this
group. Notably, this improvement seems to be
associated with greater use of correction boluses.
The downside of these otherwise encouraging
assessments was highlighted in the study by
Dover and colleagues [22]. Although CGM met-
rics improved across the study group (n = 572),
they also demonstrated a deterioration of at least
5% TIR in a subset of patients (n = 125) and that
this was significantly associated with higher
levels of socio-economic deprivation. This must
be included in learnings from the enforced
shielding during COVID-19 in order to ensure
that a care gap does not emerge in the applica-
tion of diabetes technology once the COVID-19
pandemic is over.
Most of the studies included did not include
a formal telemedicine component, rather they
collected data from an observational standpoint
and made no assessment of the nature of tele-
medicine contacts between patients and their
diabetes HCPs, although these are acknowl-
edged to have happened. However, 4/27 studies
did involve an active telemedicine intervention
and in each of these studies [23–26] there was
an improvement in glucose metrics. Most tell-
ingly, in the study by Alharthi [26], CGM users
were categorized into two groups, one that
participated in a single telemedicine consult
during the 6-week lockdown study period
(n = 61) and one that did not (n = 40). Those
who attended a telemedicine visit had a signif-
icant improvement in average glucose, GMI,
%TIR and %TAR. In contrast, there were no
significant changes in any CGM metrics in the
group that did not receive a telemedicine
consultation.
DIABETES CONTROL IN ABSENCE
OF TELEMONITORING
The question must be asked as to the glucose
control of people with diabetes who have not
had access to telemonitoring with CGM. Over-
all, the expected deterioration in glycaemic
control is only variably evident. Two studies
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have indicated that people with T2D have seen
their HbA1c rise during COVID [27, 28] but in at
least one of these studies the rise has been for
people with diabetes less than 50 years of age
[27] but not older. Balancing these observations
are studies showing that COVID-19 home con-
finement did not negatively impact glucose
control in patients with T2D [29], although
older age and insulin therapy are associated
with greater risk of deterioration of glucose
control, and a separate study has observed a fall
in HbA1c during the COVID restrictions [30]. A
study from the Netherlands found that, during
the COVID-19 lockdown, people with relatively
well-controlled T1D or T2D showed increased
stress and weight gain but no deterioration in
glucose control [31]. A section of the study
group was CGM users so it is hard to interpret
these findings. In T1D, an increase both in
average glucose and HbA1c was reported in a
small cohort of people in India [32]; however,
this appears to be mainly due to non-availabil-
ity of insulin or self-monitoring blood glucose
(SMBG) strips during the lockdown period.
COSTS OF COVID IN DIABETES
POINT TO NEED FOR EFFECTIVE
TELEMEDICINE
For healthcare services, a move towards tele-
monitoring for care of people with chronic
conditions, including diabetes, has been part of
a long-term plan [33]. However, the COVID-19
public health emergency has forced the accel-
eration of this process. The increased risks of
severe disease and death for people with dia-
betes contracting COVID are evident but these
are also matched by a significant financial
impact. An analysis of hospital admissions
across Europe [34] during the period Jan-
uary–June 2020 has calculated that the total
costs for treating people with diabetes admitted
to hospital with COVID-19 during this period
was €3.38 billion, which is approximately 24%
of all COVID-related admission costs. Of par-
ticular note is that varying costs are associated
with the type of diabetes and the level of
metabolic control [34]. Thus, each admission
for a person with T1D who has HbA1c close to
target\7.5% (58 mmol/mol) is associated with
a cost of €28,997, whereas a person with T1D
and higher HbA1c (C 7.5%; 58 mmol/mol)
would cost €57,244. For people with T2D these
costs are €25,018 and €46,130. The lesson is that
maintaining good glucose control is of high
value, even if telemonitoring and telemedicine
have not prevented a COVID-related
hospitalization.
HYPERGLYCAEMIA IS
A SIGNIFICANT RISK FACTOR
FOR COVID INFECTION,
HOSPITALIZATION AND DEATH
That diabetes is a significant risk factor for
COVID infection and subsequent severe disease
is accepted [4, 6, 35]. A significant part of this
risk profile can be attributed to hyperglycaemia.
Amongst a cohort of 183 people with diabetes
in Israel, HbA1c was shown to predict con-
tracting COVID-19 and subsequent hospitaliza-
tion [33] (Fig. 2). Amongst this cohort, those
with an HbA1c of 8.0–8.9% (64–74 mmol/mol)
had a 1.56 increased odds ratio contracting
COVID compared to people with HbA1c\7.0%
(\53 mmol/mol), and those with HbA1c
C 9.0% (C 75 mmol/mol) had an odds ratio of
1.84. Regarding hospitalization following
infection, compared to an HbA1c\7.0%
(\53 mmol/mol), levels of 7.0–7.9% (53-
63 mmol/mol), 8.0–8.9% (64–74 mmol/mol)
or C 9.0% (C 75 mmol/mol) increased the odds
of hospitalization by 2.4, 3.2 and 3.4, respec-
tively [36].
Regarding mortality from COVID in hospi-
tal, the OpenSAFELY analysis of over 17 million
primary care records [37] indicates that, when
adjusted for all covariables, adults with diabetes
and HbA1c of\7.5% (\58 mmol/mol) have a
1.31 hazard ratio for death with COVID, which
rises to 1.95 for HbA1c C 7.5%
(C 58 mmol/mol). More specifically, Holman
and colleagues [4] showed that people with T1D
and HbA1c C 10% (86 mmol/mol) had a 2.23-
fold increased risk of death compared to those
with an HbA1c of 6.5–7.0% (48–53 mmol/mol).
People with T2D had a 1.22-fold risk of death
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with HbA1c levels C 7.6% (59 mmol/mol)
compared to those with HbA1c of 6.5–7.0%
(48–53 mmol/mol), rising to 1.36 above 9.0%
(75 mmol/mol) and 1.61 above 10%
(85 mmol/mol). These significant associations
reinforce the evidence that hyperglycaemia at
admission increases in-patient mortality with
COVID-19, both for people with pre-existing
diabetes or without [38–40]. The importance of
hyperglycaemia in COVID infection is linked to
a number of hypotheses [41–43] whereby SARS-
CoV-2 infection is facilitated then potentiated
by the generalized multisystemic inflammation
process observed that further drives the hyper-
glycaemic state.
Importance of Telemonitoring Following
COVID-Related Admission
and Hyperglycaemia
Glucose telemonitoring is emphasised for
patients admitted to hospital with COVID, both
those with diabetes and those without diabetes
but high admission glucose. Using CGM in 35
patients with COVID and diabetes, Shen et al.
[44] showed that %TAR[ 160 mg/dL
([8.9 mmol/L) or %TBR\70 mg/dL
(\3.9 mmol/L) is associated with up to 2.45-
fold increased odds ratio of ICU admission,
mechanical ventilation or hypotension/multi-
ple organ dysfunction. Length of hospital stay
was also associated with %TAR and %TBR. Sig-
nificantly, the odds ratio for adverse outcomes
was also increased with glycaemic variability
(GV) above a coefficient of variation (CV) of
36%. The implication is that maintaining TIR
70–160 mg/dL (3.9–8.9 mmol/L) as close to 70%
as possible is a management strategy that
should be targeted for all patients admitted to
hospital with hyperglycaemia and COVID.
The need to maintain good glucose control is
supported by the analysis of Klonoff and col-
leagues [45], who noted that severe hypergly-
caemia ([250 mg/dL/[13.9 mmol/L) on
days 2–3 after admission was independently
associated with high mortality (adjusted hazard
ratio 7.17; 95% CI 2.62–19.62) compared with
patients with glucose\140 mg/dL (\7.8 mmol/
L). Notably, reducing high admission glucose to
141–180 mg/dL (7.8–10 mmol/L) by day 2–3 was
shown to significantly reduce the risk of
Fig. 2 Hyperglycaemic risk profiles for COVID-related
disease and mortality. }For HbA1c\ 7.5%
(58 mmol/mol) [37]. *For HbA1c C 7.6%
(60 mmol/mol) [4]. Risk profiles compared to HbA1c\
7.0% (53 mmol/mol). Data derived from relative risk [4],
hazard ratio [37] or odds ratio [36] assessments. Risk
factors categorized by separate diabetes type indicated on
the bars only where known
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mortality [45]. The impact of concurrent COVID
with DKA and hyperglycaemic hyperosmolar
syndrome (HSS) on post-admission outcomes
[46] also argues for the application of immediate
telemonitoring and glucose-lowering treatment
following admission. Given that regular glucose
monitoring using standard point-of-care testing
exposes hospital teams to risk of COVID infec-
tion, the importance of telemonitoring that aids
anti-glycaemic therapy whilst reducing frequent
patient contact is strongly indicated.
Risk of New-Onset Diabetes Because
of COVID-19 Infection
Evidence that infection with COVID-19 may
precipitate diabetes is also emerging [42]. The
SARS-CoV virus, which caused the SARS epi-
demic, is reported to bind angiotensin-con-
verting enzyme 2 (ACE2) receptors in the
pancreas with consequent damage to islet cells
and reduced insulin release [40, 47]. Compared
to healthy siblings, SARS infection resulted in
symptomatic T2D during hospitalization in half
of cases, with 5% remaining diabetic 3 years
later. During the COVID-19 pandemic, SARS-
CoV-2 infection has been associated with the
subsequent onset of insulin-dependent diabetes
[48], presenting with DKA in a young man with
severe loss of b-cell function but no islet-specific
autoantibodies. Direct SARS-CoV-2-mediated b-
cell damage is proposed as the cause of the T1D
manifested in this case [48]. Similar associations
have been made for children [49].
NEWLY DIAGNOSED DIABETES
AND NEED FOR EARLY GLUCOSE
CONTROL
In addition, several strands of evidence indicate
that newly diagnosed diabetes should be a clear
target for immediate glucose control. In the
context of COVID-19, people with newly diag-
nosed diabetes are at most risk of COVID-re-
lated admission to intensive care or death [50],
with three times the risk of people with pre-
existing diabetes [2, 50] and an increased length
of stay in hospital. This increased mortality has
been linked to more severe organ damage
amongst people with newly diagnosed diabetes
[51], suggestive of a metabolic disruption that is
mitigated following diabetes therapy.
In these studies, the designation of ‘newly
diagnosed’ refers to their hyperglycaemia state
detected in hospital rather than a ‘recent diag-
nosis’. However, the increased risk is not solely
due to hyperglycaemia, since their glucose
levels are typically lower than people with pre-
existing diabetes or without diabetes at the
point of admission [2]. Of course it is difficult to
ascertain if a proportion of these patients may
have had undiagnosed diabetes at the point of
infection. Therefore it is important to better
understand the metabolic fragility of a person
with diabetes at the point of diagnosis and
immediately thereafter, and also to take steps to
overcome this state. Further research is required
to establish the extent and duration of ‘new
onset’ risk following diagnosis and the patho-
physiology associated with it. This would be an
important role for telemonitoring with CGM
systems, which can both help educate the new
patient and also help improve their glycaemic
dysregulation.
Managing New-Onset Type 1 Diabetes
Using Telemedicine
Insulin initiation in new-onset T1D is another
important aspect of telemedicine for people
with diabetes that has typically emphasised in-
person clinic attendance and face-to-face train-
ing. This standard approach has been another
casualty of the COVID-19 pandemic, despite the
evidence that this group are at high risk of
COVID-related harm. In two case reports, tele-
medicine has been used effectively and safely as
part of the insulin initiation, including dose
titration, as well as to provide education on
diabetes management and support. These
reports describe a newly diagnosed adult and a
12-month-old child [52]. Both cases did involve
initial emergency hospital admission and
assessment, and both patients were started on
either multiple daily injections of insulin (MDI,
adult subject) or on continuous subcutaneous
insulin infusion (subcutaneous insulin infusion
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(CSII), paediatric subject) as part of in-hospital
care. However, follow-up glycaemic monitor-
ing, insulin adjustment and education were
substantially provided through telemedicine
and using ambulatory glucose profiles and
interpretive summary reports generated
through CGM initiated while in hospital. In
both cases, the subjects were successfully man-
aged via telemedicine. In the UK, led by the
national Diabetes Technology Network, a
donation of sensors was used to support rapid
discharge and remote follow-up of patients in
this setting [53].




People with diabetes have significant COVID-
19-specific worries related to their diabetes.
Social distancing gives rise to stressors that lead
to anxiety and this may be exacerbated for
people with diabetes who can be subject to
advice for stricter isolation. A survey of 1396
people with diabetes in Denmark [54] found
that the most prevalent diabetes-specific worry
related to COVID-19 was fear of being overly
affected by the virus (56% respondents) along
with being labelled as a high-risk group (39%
respondents) and an inability to manage their
diabetes if infected (28% respondents). In gen-
eral, improvements in psychosocial health
started to occur during the first reopening phase
after the initial survey responses.
It is likely that this fear of infection con-
tributes to a reluctance to visit medical centres
during COVID. There is evidence that rates of
admission for significant macrovascular disease
are lower than usual, which may reflect reluc-
tance of people to attend hospital. Although
not specific to diabetes, data from Kaiser Per-
manente in the USA showed a 48% reduction in
hospitalizations for acute myocardial infarction
during the early weeks of lockdown [55]. Simi-
larly, a study in France [56] has indicated that,
although the overall incidence of stroke
remained the same, fewer patients presented for
neurology assessment within the therapeutic
window as a consequence of anxieties over
COVID transmission.
Fear of attending hospitals since March 2020
has had significant impacts for people with
diabetes, with consequent outcomes for non-
COVID severe illness [57]. A survey of 4075
paediatricians in the UK and Ireland [58] indi-
cated that symptomatic DKA was the most
common problem that resulted from fear of
attendance, separately from new-onset diabetes.
Reports indicate that during the COVID-19
pandemic lockdown, the rate of DKA has
increased amongst children with newly diag-
nosed T1D [59], including an increase in more
severe cases [59–61]. This is accompanied by
reports of more prevalent presentation of severe
DKA in COVID-positive children with estab-
lished T1D [61]. It is likely that the increase in
severity in new or established cases coincides
with delayed attendance at hospitals due to fear
of COVID. Regular education of the whole
society about the symptoms of diabetes could
contribute to faster diagnosis of T1D and
reduction of DKA prevalence, along with more
rigorous adherence to ‘sick-day rules’ which are
recommended for established T1D in such sit-
uations [62, 63].
Risk of DKA for people with T2D may be
exacerbated by COVID infection. A series of
cases have been described in which people with
T2D and no history of DKA have presented at
hospital with new-onset DKA, likely precipi-
tated by COVID infection [64]. People with T1D
are also at highest risk of DKA during COVID-
related social lockdown, possibly related to
potential changes in access to insulin or SMBG
test strips [64]. Under these circumstances the
value of telemonitoring with CGM can make
the difference between early intervention and
treatment, or a potentially life-threatening
acute DKA episode. Both the FUTURE study in
three specialist diabetes centres in Belgium [65]
and the larger nationwide RELIEF study in
France [66] have reported a significant fall in
acute diabetes events (ADE), including DKA,
after reimbursement of the FreeStyle Libre CGM
system was approved within each health ser-
vice. A recent retrospective, real-world analysis
of a medical insurance claims database in the
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USA has shown a similar fall in ADE and related
hospitalizations, including for DKA, once the
FreeStyle Libre system was prescribed for people
with diabetes [67]. Given the additional
COVID-related risks for people with diabetes
and prior hospitalization for DKA [8], the ben-
efits of telemonitoring are strongly emphasised
as they enable diabetes care at a distance and






The current reliance on telemedicine for
managing people with diabetes will persist, not
just in the near future but as part of standard care
as diabetes services evolve to accommodate the
successes and challenges of the COVID pan-
demic. However, it is important to acknowledge
that telemedicine must be viewed in context.
Although telemedicine during COVID has been
largely welcomed as a positive experience in
people with T1D, it is not universally appreci-
ated. A survey of 7477 individuals across Europe,
North America, South American, Africa and Asia
has highlighted both the pros and cons [68].
Thirty per cent of respondents reported that
their healthcare access had suffered during
COVID and the majority (86%) found remote
consultations useful, with 75% indicating that
they would continue with remote appointments
in the future. This covered all age groups,
including those over 65 years old. However, a
group of respondents reported a negative per-
ception of telemedicine. These were typically
male and poorly controlled (HbA1c[9.0%). The
context of their reluctance to participate in tel-
emedicine was unclear, whether it was down to
lack of engagement with their own diabetes or
lack of engagement with telemedicine.
What is clear is that telemedicine without
telemonitoring in diabetes is a harder proposi-
tion. People with diabetes are at greater risk at
every step of the natural history of COVID-19,
from first infection through to severe disease,
hospitalization and death [6, 35, 36]. Impor-
tantly, these risks reflect known attributes of
people with diabetes, including type and dura-
tion of diabetes, longer-term control (HbA1c),
short-term hyperglycaemia, comorbid and
intercurrent disease, ethnicity and socio-eco-
nomic status. Practical guidance for managing
people with diabetes during COVID-19 has been
published [62] and telemonitoring with CGM
means that important parts of the risk profiles
can be managed, both via telemedicine and
through in-person consultation at a diabetes
centre. The future of telemedicine is not simply
about keeping people away from hospitals, it is
equally about knowing who should be asked to
come to the clinic and when. Thus, we see a
future for diabetes care that prioritises people
with diabetes for appropriate consultations based
on their glucose metrics and other risk markers.
Naturally, further adoption of telemedicine is
part of clinical care for the many people whose
diabetes can be managed with a clear view of
their glucose metrics. It must also be pointed out
that certain care processes will require in-clinic
visits at a certain frequency, e.g. diabetes-related
foot disease. Similarly, people with more acute
disease will not easily fit the transition to tele-
medicine. These include those with significant
hypoglycaemia unawareness or fear of hypogly-
caemia, as well as people with frequent diabetes-
related admission for DKA or hyperosmolar
hyperglycaemic state (HHS) [69]. This also
applies to people with diabetes with comorbid
disease and risks for cardiovascular or cere-
brovascular events, who should be seen in-clinic






The virtual diabetes clinic has been a goal of
healthcare systems and expert diabetes profes-
sionals for some time. Based around the grow-
ing number of technologies that enable diabetes
care, telemedicine has been proposed as an
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important solution to the need to expand care
for the benefit of people with diabetes, whilst
improving efficiencies and rationalizing costs.
As recently as February 2020, less than a month
before the COVID pandemic was declared, an
expert panel endorsed the opportunities and
challenges of making telemedicine a standard of
care for the management of diabetes [33]. In
doing so they identified barriers for system
interoperability within a diabetes health
ecosystem and HCP reimbursement. In the UK,
an expert panel recommended a risk stratifica-
tion and risk-based follow-up approach using
telemonitoring to help stratify people into red,
amber or green categories [69].
The COVID-19 pandemic has shortcut some
of these important conversations, disrupting
the system and driving change in a manner that
could not have been predicted. In doing so, the
most agile services have emphasised and adop-
ted systems and technologies that support
people with diabetes in new models of care that
minimise their need to attend busy medical
centres. It is not a coincidence that the early
adopters of new service designs are paediatric
diabetes clinics [9, 23, 70], one of which reports
more than 80% of scheduled visits had been
accomplished by telemedicine within 3 weeks
of starting, with fewer missed appointments
[70].
It can be argued that paediatric services are
more agile in this regard because diabetes
management enabling technology is more
prevalent amongst younger children with dia-
betes [71]. The value of this is confirmed by
recent outcomes from the SWEET project, a
multinational network of more than 100 pae-
diatric diabetes centres with a mission to
establish standards of care in paediatric diabetes
worldwide [72]. Data on 25,654 children and
adolescents from SWEET [73] showed that
children and adolescents using continuous CSII
pumps, CGM systems or both had significantly
lower HbA1c compared to those using insulin
injections and SMBG. The proportion of DKA
episodes was lower in the group using an insulin
pump alone or in tandem with a CGM sensor.
Of note, reported episodes of severe hypogly-
caemia were lower in the group using an insulin
pump without a CGM sensor, but increased in
the group using CGM alone, compared to those
using insulin injections and SMBG. This would
suggest that the full impact of each of these
enabling technologies, though demonstrated,
can be further improved.
Together, these real-world insights indicate
that the need for technology interoperability is
already being met for effective telemedicine in
diabetes, with new ways of working that lever-
age existing digital health ecosystems. It is clear
that this can improve in the future, with sys-
tematic application of additional tools that can
enhance the emerging practice of telemedicine,
but it is effective now. A further barrier to tele-
medicine is also being dismantled as a conse-
quence of COVID, that of reimbursement.
Healthcare payers are widening existing provi-
sions for telemedicine or creating them where
they did not exist [74–76].
CONCLUSIONS
Telemedicine and telemonitoring have been
transformed from an aspirational goal to
become the de facto standard of care for dia-
betes management during the COVID-19 public
health emergency in the developed world. This
has been in response to the need to protect
people with diabetes who are at immediate and
greater risk of severe disease, hospitalization
and death from COVID-19. However, we must
acknowledge that COVID is also an instructive
use case that highlights the vulnerability of
people with diabetes in situations that disrupt
the process of standard care. Ultimately, as well
as managing people with diabetes at a distance,
the value of routine telemonitoring must also
be to identify groups of at-risk individuals who
need in-person consultation and care.
Telemonitoring of glucose data has been an
invaluable tool in maintaining glycaemic con-
trol for a significant subset of those able to
access this technology, most evidently for peo-
ple with T1D, including paediatric and adult
groups. The case for wider application of glu-
cose telemonitoring is clear but still faces sig-
nificant hurdles. Central to these is
acknowledgement of the value of telemonitor-
ing and reimbursement for this along with
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increased access to CGM systems. The
cost–benefit calculation has been strongly
weighted towards the benefits during COVID
but further action is needed to conclusively
demonstrate the long-term financial savings.
Education in regard of telemonitoring and tel-
emedicine is also critical to the successful
implementation of technologies that better
enable diabetes care, both for HCPs and for
people with diabetes. Just as important are the
imperatives to manage data for enhanced dia-
betes care. The COVID public health emergency
has shown what can be achieved when the
current technology is put under the spotlight,
but this can be better supported with systematic
changes to diabetes care. Integration of data
uplink and data sharing systems is a recognised
unmet need in this context. Additionally, with
better systems integration comes the require-
ment for an information technology (IT) spe-
cialist contribution, not as a support service but
as an established member of the diabetes mul-
tidisciplinary team. Action on these aspects of
diabetes digital health is a clear imperative.
Telemedicine is an acknowledged part of the
post-COVID world but telemonitoring via CGM
is still possible only for a subset of people with
diabetes. The diabetes services adapting most
quickly to the needs of care of people with
diabetes appear to be those with the most
experience and confidence of working with
diabetes health technologies and creating their
own diabetes health ecosystems. These are often
paediatric services.
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